WATERTOWN, Mass.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24TTPH&src=ctag” target=”_blank”gt;$TTPHlt;/agt; lt;a href=”https://twitter.com/hashtag/antibioticresistance?src=hash” target=”_blank”gt;#antibioticresistancelt;/agt;–Tetraphase
Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company
focused on developing and commercializing novel tetracyclines to treat
serious and life-threatening conditions, today announced five data
presentations at the 29^th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID), taking place April 13-16
in Amsterdam, Netherlands. Presentations will include information about
XERAVA^TM (eravacycline), a tetracycline antibiotic approved
for the treatment of complicated intra-abdominal infections (cIAI), as
well as data for the Company’s clinical development candidates, TP-271
and TP-6076.

The details for the data presentations at ECCMID are as follows:

Eravacycline poster presentations

Poster title: Multicenter evaluation of eravacycline MIC results
for Esherichia coli using MicroScan Dried Gram-negative MIC panels
Date
and time: Monday, April 15 from 12:30 – 1:30 p.m. CEST (6:30 – 7:30
a.m. ET)
Location: Paper Poster Arena
Poster number:
#P1735
Session information: PS098 – Diverse methodologies
for MIC testing in Gram-negatives

Poster title: In vitro activity of eravacycline and
comparators against Gram-positive bacteria collected from European
hospitals in 2017
Date and time: Monday, April 15 from 1:30
– 2:30 p.m. CEST (7:30 – 8:30 a.m. ET)
Location: Paper
Poster Arena
Poster number: #P1874
Session
information: PS107 – In vitro activity of newer antimicrobial
agents

Poster title: Surveillance of the in vitro activity of
eravacycline and comparators against clinical isolates from Europe
during 2017
Date and time: Monday, April 15 from 1:30 – 2:30
p.m. CEST (7:30 – 8:30 a.m. ET)
Location: Paper Poster Arena
Poster
number: #P1875
Session information: PS107 – In vitro
activity of newer antimicrobial agents

TP-271 poster presentation

Poster title: Safety, tolerability and pharmacokinetics of
multiple doses of TP-271, a novel fluorocycline, in normal healthy
subjects
Date and time: Monday, April 15 from 1:30 – 2:30
p.m. CEST (7:30 – 8:30 a.m. ET)
Location: Paper Poster Arena
Poster
number: #P2012
Session information: PS116 – Safety of
antibacterial agents in the clinic

TP-6076 poster presentation

Poster title: In vivo efficacy of TP-6076 in murine thigh
and lung infection models challenged with Acinetobacter baumannii
Date
and time: Monday, April 15 from 1:30 – 2:30 p.m. CEST (7:30 – 8:30
a.m. ET)
Location: Paper Poster Arena
Poster number:
#P1994
Session information: PS115 – Evaluation of diverse
antimicrobials in vitro and experimental models

Full abstracts can be found on the ECCMID website at www.eccmid.org.
Additional questions or follow up should be directed to poster authors.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using
its proprietary chemistry technology to create novel tetracyclines for
serious and life-threatening conditions, including infections caused by
many of the multidrug-resistant bacteria highlighted as urgent public
health threats by the World Health Organization and the Centers for
Disease Control and Prevention. The Company has created more than 3,000
novel tetracycline compounds using its proprietary technology platform.
Tetraphase’s lead product XERAVA^TM is approved for the
treatment of complicated intra-abdominal infections by the U.S. Food and
Drug Administration and the European Medicines Agency. The Company’s
pipeline also includes TP-271 and TP-6076, which are in Phase 1 clinical
trials, and TP-2846, which is in preclinical testing for acute myeloid
leukemia. Please visit www.tphase.com
for more company information.

Forward-Looking Statements

Any statements in this press release about our future expectations,
plans and prospects, including statements regarding our strategy, future
operations, prospects, plans and objectives, including our key
milestones for 2019 and our anticipated cash runway, and other
statements containing the words “anticipates,” “believes,” “expects,”
“plans,” “will” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including whether our commercial launch of XERAVA in
the U.S. will be successful; our cash resources and the expected revenue
will be sufficient to fund our operations for the period anticipated;
our product candidates will succeed in clinical trials and even if the
clinical trials are successful, we may never achieve regulatory approval
of such product candidates and other clinical, regulatory and commercial
risk factors discussed in the “Risk Factors” section of our annual
report on Form 10-K for the period ended December 31, 2018, filed with
the Securities and Exchange Commission on March 15, 2019. In addition,
the forward-looking statements included in this press release represent
our views as of April 8, 2019.We anticipate that subsequent events and
developments will cause our views to change. However, while we may elect
to update these forward-looking statements at some point in the future,
we specifically disclaim any obligation to do so.

Contacts

Jennifer Viera
jviera@tphase.com
617-600-7040